← Back to Search

Motivational Interviewing for Substance Use Disorders

N/A
Recruiting
Led By Margo Hurlocker, PhD
Research Sponsored by University of New Mexico
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 1 year
Awards & highlights

Study Summary

This trial will test whether using Motivational Interviewing at Intake (MII) with adults seeking outpatient addiction treatment leads to better engagement with treatment and understand why this is the case. Personnel feedback will be gathered on whether MII is feasible to implement into standard practice.

Who is the study for?
This trial is for English-speaking adults seeking outpatient treatment for alcohol or drug use, who are willing to follow study procedures and have given informed consent. It's also open to staff at the treatment programs. Participants must not be physically dependent on substances at the time of intake.Check my eligibility
What is being tested?
The study compares two approaches: usual intake procedures versus Motivational Interviewing at Intake (MII) to see which is more effective in engaging clients in addiction treatment. The trial will also assess how easy it is to integrate MII into regular practice.See study design
What are the potential side effects?
Since this trial involves counseling techniques rather than medication, traditional side effects are not expected. However, participants may experience emotional discomfort discussing their substance use during motivational interviewing sessions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants who attended the first outpatient treatment program session based on electronic medical record review
Number of participants who completed the three-month outpatient treatment program based on electronic medical record review
Number of treatment sessions attended during the three-month outpatient treatment program based on electronic medical record review
Secondary outcome measures
Change from baseline in client readiness to enter treatment on the University of Rhode Island Change Assessment Scale (URICA) at 1 hour post-intake
Score on therapeutic alliance on the Working Alliance Inventory (WAI) at 1-hour post-intake
Other outcome measures
Change from baseline in organizational capability to change on the Change Process Capability Questionnaire (CPCQ) at Year 1
Change from baseline in organizational readiness to change on the Readiness for Organizational Change (ROC) at 1 year
Change from baseline in organizational readiness to change on the Texas Christian University-Organizational Readiness to Change (TCU-ORC) at 1 year

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Motivational Interviewing at Intake (MII)Experimental Treatment1 Intervention
Clients allocated to the MII condition will receive a 90-minute pure Motivational Interviewing (MI) session.
Group II: Intake as Usual (IAU)Active Control1 Intervention
Clients allocated to the IAU condition will receive the 90-minute standard assessment that is delivered to all clients entering intensive outpatient program (IOP)/outpatient program (OP).

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,470 Previous Clinical Trials
2,619,580 Total Patients Enrolled
University of New MexicoLead Sponsor
372 Previous Clinical Trials
3,528,639 Total Patients Enrolled
Margo Hurlocker, PhDPrincipal InvestigatorUniversity of New Mexico

Media Library

Intake as Usual (IAU) Clinical Trial Eligibility Overview. Trial Name: NCT05489068 — N/A
Substance Use Disorders Research Study Groups: Motivational Interviewing at Intake (MII), Intake as Usual (IAU)
Substance Use Disorders Clinical Trial 2023: Intake as Usual (IAU) Highlights & Side Effects. Trial Name: NCT05489068 — N/A
Intake as Usual (IAU) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05489068 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the eligibility requirements to participate in this trial?

"Affirmative, the clinical trials database confirms that this medical study is actively recruiting. It was originally published on March 16th 2022 and has since been updated as of August 2nd 2022. Approximately 150 participants will be recruited from a single location."

Answered by AI

What is the upper bound for participants in this clinical experiment?

"Correct. Clinicaltrials.gov indicates that this experiment, which was initially opened on March 16th 2022, is actively enrolling participants and requires 150 patients to be recruited from one site."

Answered by AI

Who else is applying?

What state do they live in?
New Mexico
What site did they apply to?
Turning Point Recovery Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

What questions have other patients asked about this trial?

I would like to know what days how long it is what’s the outline of the study and what should the outcome be? What are the goals in this study?
PatientReceived no prior treatments
~25 spots leftby Oct 2024